Autonomix Medical, Inc.

European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company’s international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled “Systems for Assessing Neural Activity in an Eye.” The newly issued patent further expands the Company’s international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe. The European patent covers technologies designed to assess autonomic nervous system activity through the monitoring and analysis of neural activity within the eye. The patent includes systems and methods for evaluating physiologic responses through ocular measurements that may support patient assessment, treatment guidance and procedural feedback across a variety of autonomic nervous system disorders and neuromodulation applications. “This European patent represents another important step in expanding our global intellectual property footprint,” said Brad Hauser, Chief Executive Officer of Autonomix. “As we continue advancing our precision nerve-targeted technology platform, building a broad international patent portfolio remains a key strategic priority. This patent enhances protection for technologies supporting […]

Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member for Autonomix. Ms. Kalter brings more than four decades of experience across the medical device and healthcare industries, including extensive senior-level experience at Medtronic, one of the world’s largest and most diversified medical technology companies. During her tenure at Medtronic, she played a key role in regulatory, clinical and strategic initiatives spanning multiple business units and oversaw due diligence and integration activities associated with more than 27 acquisitions. Her Medtronic experience includes supporting some of the company’s most significant and innovative technologies, including the Symplicity Spyral™ Renal Denervation system, Evolut™ TAVR platform, Micra™ Transcatheter Pacing System, and PulseSelect™ Pulsed Field Ablation system. Her experience also includes involvement with the acquisition and integration of technologies that contributed to Medtronic’s expansion of its renal denervation platforms and […]

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s transvascular technology to address complex clinical challenges involving the nervous system, including pain management and precision identification of neural structures. Details of the presentations are as follows: Title: Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based AblationPresentation Type: Scientific Abstract – PosterPresenting Author: Dr. Robert Schwartz Title: Illuminating the Nervous System with Transvascular Precision-Guided TechnologyPresentation Type: SPHAIRE – PosterPresenting Author: Dr. Robert Schwartz The CIRSE 2026 Annual Congress will bring together the global interventional radiology community under the theme “Breaking barriers, expanding care,” reflecting CIRSE’s mission to expand access to high-quality interventional radiology and enable more patients to benefit from minimally invasive, […]

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain THE WOODLANDS, TX, Aug. 26, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office (USPTO), titled “Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development” on August 25, 2026. The newly issued patent covers medical systems incorporating a surgical instrument with one or more delivery elements and a controller configured to regulate treatment based, at least in part, on physiological feedback signals from a targeted tissue region or surrounding tissues. The patent specifically covers systems capable of controlling the quantity and delivery of therapeutic fluid based on its distribution within the targeted tissue, as well as systems incorporating imaging and sensing capabilities. Importantly, the issued patent includes applications in which the targeted tissue region comprises a tumor and the therapeutic fluid is configured to effect neural ablation to reduce cancer pain. The patent also covers the use of denervating agents, sympathetic […]

THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses. Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction. In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series E-1 warrants to purchase an aggregate of […]

Final histology and laboratory analyses support the study’s safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company’s submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models. Final histopathology and laboratory analyses support the positive safety and performance outcomes previously reported by the Company. Data generated from the study are expected to support Autonomix’s FDA submissions and represent an important component of the Company’s regulatory package as it advances its proprietary technology. “The successful completion of this GLP pre-clinical study represents a critical step in our regulatory and clinical development strategy,” said Brad Hauser, Chief Executive Officer of Autonomix. “The final pathology and laboratory findings reinforce the positive safety and performance profile we have observed throughout the study and provide important validation of our platform. This […]

Recognition honors one of the medical technology industry’s most influential innovators, whose career has helped shape modern cardiovascular care THE WOODLANDS, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today congratulated its Chief Medical Officer, Robert Schwartz, M.S., M.D., FACC, on being named the recipient of the 2026 Cardiovascular Tech Forum (CTF) Lifetime Achievement Award, recognizing his extraordinary career and lasting contributions to cardiovascular medicine, innovation and medical technology. Dr. Schwartz will be honored during Octane’s 2026 Cardiovascular Tech Forum on September 18, 2026, in Newport Beach, California. The annual award recognizes individuals whose pioneering work has transformed the cardiovascular technology landscape through scientific achievement, clinical innovation and entrepreneurial leadership. Throughout his distinguished career, Dr. Schwartz has authored more than 500 scientific publications, holds more than 200 patents and has founded multiple medical technology companies whose innovations have changed how the field operates, including the Watchman device, which he co-invented and which was later acquired by Boston Scientific. “Rob’s career has been defined by a relentless pursuit of innovation that has improved the lives of countless patients around the world,” said Brad […]

Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic nervous system disorders and broader organ-function applications THE WOODLANDS, TX, Aug. 04, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands the Company’s intellectual property protection for technologies designed to sense, map and selectively target nerves associated with tumors, cancer-related pain, organ function and other autonomic nervous system disorders. The patent covers minimally invasive systems designed to sense and map electrophysiological activity in nerves associated with tumors or metastatic cells and use that information to guide targeted treatment. The technology includes catheter-based microsurgical tools designed to record neural signals and deliver energy or therapeutic agents to selectively block or modulate identified nerves. The patent describes technologies intended to: Sense and map electrophysiological activity associated with tumors or metastatic cells; Use neural mapping information to identify and guide treatment of targeted nerves; Selectively block or modulate tumor-associated nerves […]

Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation THE WOODLANDS, TX, July 24, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced positive results from a preclinical study demonstrating the ability of its proprietary neural sensing platform to detect, localize and confirm changes in renal neural activity. The study successfully demonstrated Autonomix’s ability to identify neural signals associated with nerve activity along the renal artery and surrounding tissue, providing direct physiological feedback before and after targeted ablation. The findings support further development of the Company’s neural sensing platform for physiology-guided renal denervation procedures. In the study, the Autonomix catheter was deployed endovascularly within the renal arteries of an animal subject. Neural activity was recorded across multiple anatomical locations, with distinct signal signatures identified and consistent neural activity patterns observed. Following targeted ablation, researchers observed attenuation of previously detected neural signals, supporting the platform’s potential ability to both identify neural targets and assess changes in neural activity following therapy. “These findings represent a critical milestone in validating our ability to both sense […]

Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX, July 23, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” further strengthening the Company’s intellectual property portfolio supporting its proprietary autonomic nervous system technologies. The newly issued patent broadly covers systems, devices and methods for monitoring physiologic signals to assess autonomic nervous system (ANS) activity, including technologies designed to evaluate sympathetic and parasympathetic nervous system function through multiple physiologic assessment techniques. The patent also encompasses technologies that may support patient selection, procedural guidance, treatment feedback and post-treatment monitoring across a broad range of neuromodulation applications. “Our vision has always extended well beyond developing a single product. We are building a differentiated technology platform capable of transforming how physicians identify, target and treat diseases involving the peripheral nervous system,” said Brad Hauser, Chief Executive Officer of Autonomix. “This newly issued patent further strengthens our innovation and technological foundation supporting that vision by protecting innovations designed […]